Food based phytochemical luteolin their derivatives, sources and medicinal benefits
Keywords:
Luteolin, Flavonoid, Derivatives, Source, Health benefitsAbstract
Luteolin is a type of flavonoid and a 38, 48, 5, 7-tetra hydroxyl flavone with a yellow crystalline appearance. Luteolin is widely present in different plant families such as, Lamiacea, Arecaceae, Brassicaceae, Campanulaceae, Asteraceae, Resedaceae and Scrophulariaceae. Luteolin mostly found in edible plants and most important food based phytochemical. Dietary sources of luteolin such as, celery, peppers, carrots, peppermint, olive oil, thyme, oregano and rosemary, etc. On the base of luteolin content among other sources oregano is the better source with 1028.75mg/100g contents. Flavonoids are important component of plants, and widely used in traditional medicine to cure the different type of diseases. Luteolin has different health benefits such as, anti-inflammatory, sun protectant, anti-oxidant, improve heart function, neurological impairments, anti-cancer and many more. Luteolin has many possible mechanisms involved in different biological activities such as, stabilization of p53, modulation of ROS levels, and reduction of NF- kappaB, reduction of AP-1 activity and inhibition of PI3K.
References
Harborne JB, Williams CA, 2000. Advances in flavonoid research since 1992. Phytochemistry, 55: 481–504.
Birt DF, Hendrich S, Wang W, 2001. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther., 90: 157–177.
Knekt P, Jarvinen R, Seppanen R, Hellovaara M, Teppo L, Pukkala E, Aromaa A, 1997. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am. J. Epidemiol., 146: 223–230.
Neuhouser ML, 2004. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr. Cancer, 50: 1–7.
Ross JA, Kasum CM, 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 22: 19–34.
Chan TS, Galati G, Pannala AS, Rice-Evans C, O’Brien PJ, 2003. Simultaneous detection of the antioxidant and pro-oxidant activity of dietary polyphenolics in a peroxidase system. Free Radic. Res., 37: 787–794.
Hempel J, Pforte H, Raab B, Engst W, Bohm H, Jacobasch G, 1999. Flavonols and flavones of parsley cell suspension culture change the antioxidative capacity of plasma in rats. Nahrung, 999; 43: 201–204.
Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N, 1998. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett., 438: 220–224.
Le-Marchand L, 2002. Cancer preventive effects of flavonoids–a review. Biomed. Pharmacother., 56: 296–301.
Li YL, Li Y, Wang NL, Yao XS, 2008. Flavonoids and a New Polyacetylene from Bidens parviflora Willd. Molecules, 13; 1931-1941.
Harborne BJ, Baxter H, 1999. The Handbook of Natural Flavonoids. John Wiley & Son.
Elbandy M, Elbandy M, Miyamoto T, Dubois MAL, 2007. Sulfated Lupane Triterpene Derivatives and a Flavone C-Glycoside from Gypsophila Repens. Chem. Pharm. Bull., 55; 808-811.
Materska M, Piacente S, Stochmal A, Pizza C, Oleszek W, Perucka I, 2003. Isolation and structure elucidation of flavonoid and phenolic acid glycosides from pericarp of hot pepper fruit Capsicum annuum L. Phytochemistry, 63; 893-8.
Xie H, Wang T, Matsuda H, Morikawa T, Yoshikawa M, Tanib T, 2005. Bioactive Constituents from Chinese Natural Medicines. Inhibitory Effect on Aldose Reductase and Structures of Saussureosides A and B from Saussurea medusa Chem. Pharm. Bull., 3; 1416—1422.
Chan K, 2005. Chinese medicinal materials and their interface with Western medical concepts. J. Ethnopharmacol., 6; 1–18.
Hayashi T, Sawa K, Kawasaki M, Arisawa M, Shimizu M, Morita N, 1988. Inhibition of cow’s milk xanthine oxidase by flavonoids. J. Nat. Prod., 51: 345–348.
Lu Y, Foo LY, 2002. Polyphenolics of Salvia–a review. Phytochemistry, 59(2); 117-40.
Markham KR, 1988. The major flavonoids of an antarctic Bryum. Phytochemistry, 27(9); 2843-2845.
Mues R, 1983. Specie specific flavone glucuronidase in elodea species. Biochemis. Syst. Ecol., 11; 261-261.
Mitchell KA, Markham KR, Bayly MJ, 2001. Flavonoid characters contributing to the taxonomic revision of the Hebe parviflora complex. Phytochemistry, 56(5); 453-61.
Mansour RMA, Ahmed AA, Saleh NAM, 1983. Flavone glycosides of some Launaea species. Phytochemistry, 22 (11); 2630-2631.
Abdalla MF, Saleh NAM, Gabr S, Abu-Eyta AM, El-Said H, 1983. Flavone glycosides of Salvia triloba. Phytochemistry, 22(9); 2057-2060.
Markham KR, Porter IJ, 1974. Flavonoids of the liverwort Marchantia polymorpha. Phytochemistry, 13(9); 1937-1942.
Markham KR, Porter LJ, 1975. Isoscutellarein and hypolaetin 8-glucuronides from the liverwort Marchantia berteroana. Phytochemistry, 14(4); 1093-1097.
EI-Negoumy SI, Mansour RMA, 1989. Grasas Aceites (Seville). 40; 87.
Brown NE, Ghazala H, Rizwani K, Ghani U, Ahmad VU, 1990. Flavone Glycosides of Caralluma tuberculata. Pak. J. Pharm Sci., 3(2); 27.
Williams CA, 1979. The leaf flavonoids of the orchidaceae. Phytochemistry, 18(5); 803-813.
Miean KH, Mohamed S, 2001. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem., 49; 3106–3112.
Mencherini T, Picerno P, Scesa C, Aquino R, 2007. Triterpene, Antioxidant, and Antimicrobial Compounds from Melissa officinalis. J. Nat. Prod., 70; 1889–1894.
Seelinger G, Merfort I, Wolfle U, Schempp CM, 2008. Anti-carcinogenic effects of the flavonoid luteolin. , 13(10); 2628-51.
Lin Y, Shi R, Wang X, Shen HM, 2008. Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr. Cancer Drug Targets, 8(7); 634–646.
Pitot HC, 1993. Multistage carcinogenesis–genetic and epigenetic mechanisms in relation to cancer prevention. Cancer Detect. Prev., 17; 567–573.
Hanahan D, Weinberg RA, 2000. The hallmarks of cancer. Cell, 100; 57–70.
Galati G, Teng S, Moridani MY, Chan TS, O’Brien PJ, 2000. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug. Metabol. Drug. Interact., 17; 311–349.
Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M, Sata M, 2006. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatomacells: an implication for the antitumor potential of flavonoids. Cancer Res. 66; 4826-4834.
Fang J, Zhou Q, Shi XL, Jiang BH, 2007. Luteolininhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 28; 713-723.
Manju V, Nalini N, 2007. Protective role of luteolin in 1, 2-dimethylhydrazineinduced experimental colon carcinogenesis. Cell Biochem. Funct., 25; 189-194.
Byun S, Lee KW, Jung SK, Lee EJ, Hwang MK, Lim SH, Bode AM, Lee HJ, Dong Z, 2010. Luteolin inhibits protein kinase C (epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Res., 70(6); 2415-23.
Brody JS, Spira A, 2006. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc. Am. Thorac. Soc., 3; 535–537.
Perwez HS, Harris CC, 2007. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer, 121; 2373–2380.
Karin M, Lawrence T, Nizet V, 2006. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell, 124; 823–835.
Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C, 2001. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol. Exp. Ther., 296; 181–187.
Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ, 2004. Flavonoids Inhibit Tumor Necrosis Factor-{alpha}-Induced Up-Regulation of Intercellular Adhesion Molecule-1 (ICAM-1) in Respiratory Epithelial Cells through Activator Protein-1 and Nuclear Factor-{kappa} B: Structure-Activity Relationships. Mol. Pharmacol., 66;683–693.
Kumazawa Y, Kawaguchi K, Takimoto H, 2006. Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr. Pharm. Des., 12;4271–4279.
Kotanidou A, Xagorari A, Bagli E, Kitsanta P, Fotsis T, Papapetropoulos A, Roussos C, 2002. Luteolin Reduces Lipopolysaccharide-induced Lethal Toxicity and Expression of Proinflammatory Molecules in Mice. Am. J. Respir. Crit. Care Med., 165;818–823.
Tormakangas L, Vuorela P, Saario E, Leinonen M, Saikku P, Vuorela H, 2005. In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem. Pharmacol., 70;1222–1230.
Chen CY, Peng WH, Tsai KD, Hsu SL, 2007. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci., 81;1602–1614.
Xagorari A, Roussos C, Papapetropoulos A, 2002. Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br. J. Pharmacol., 136;1058–1064.
Karin M, 2004. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann. Rheum. Dis., 63(Suppl 2):ii62–ii64.
Hayden MS, Ghosh S, 2004. Signaling to NF-kappa B. Genes Dev., 18:2195–2224.
Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ, 2004. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappa B: structure-activity relationships. Mol. Pharmacol., 66;683–693.
Devasagayam TP, Subramanian M, Singh BB, Ramanathan R, Das NP, 1995. Protection of plasmid pBR322 DNA by flavonoids against single-stranded breaks induced by singlet molecular oxygen. J. Photochem. Photobiol. B., 30;97–103.
Hu C, Kitts DD, 2004. Luteolin and luteolin-7-O-glucoside from dandelion flower suppress iNOS and COX-2 in RAW264.7 cells. Mol. Cell. Biochem., 265;107–113.
Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M, 2005. Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell, 120;649–661.
Karin M, Greten FR, 2005. NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 5;749–759.
Ross JA, Kasum CM, 2002. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 19–34.
Nimnual AS, Taylor LJ, Bar-Sagi D, 2003. Redox-dependent down regulation of Rho by Rac. Nat. Cell. Biol., 5;236–241.
Robak J, Shridi F, Wolbis M, Krolikowska M, 1988. Screening of the influence of flavonoids on lipoxygenase and cyclooxygenase activity, as well as on nonenzymic lipid oxidation. Pol. J. Pharmacol. Pharm., 40;451–458.
Lien EJ, Ren S, Bui HH, Wang R, 1999. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic. Biol. Med., 26;285–294.
Nagao A, Seki M, Kobayashi H, 1999. Inhibition of xanthine oxidase by flavonoids. Biosci. Biotechnol. Biochem., 63;1787–1790.
Sen N, Das BB, Ganguly A, Banerjee B, Sen T, Majumder HK, 2006. Leishmania donovani: intracellular ATP level regulates apoptosis-like death in luteolin induced dyskinetoplastid cells. Exp. Parasitol., 114;204–214.
Leung HW, Kuo CL, Yang WH, Lin CH, Lee HZ, 2006. Antioxidant enzymes activity involvement in luteolin-induced human lung squamous carcinoma CH27 cell apoptosis. Eur. J. Pharmacol., 534;12–18.
Manju V, Nalini N, 2005. Chemopreventive potential of luteolin during colon carcinogenesis induced by 1,2-dimethylhydrazine. Ital. J. Biochem., 54;268–275.
Harris GK, Qian Y, Leonard SS, Sbarra DC, Shi X, 2006. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells. J. Nutr., 136;1517–1521.
Chung JH, 2003. Photoaging in Asians. Photodermatol. Photoimmunol. Photomed., 19;109 -21.
Tanaka K, Hasegawa J, Asamitsu K, 2005. Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide. J. Pharmacol. Exp. Ther., 315;624–30.
Ala-aho R, Kahari VM, 2005. Collagenases in cancer. Biochimie., 87;273–86.
Brennan M, Bhatti H, Nerusu KC, 2003. Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen damage in UV-irradiated human skin. Photochem. Photobiol., 78; 43–8.
Kim YG, Sumiyoshi M, Sakanaka M, 2009. Effects of ginseng saponins isolated from red ginseng on ultraviolet B-induced skin aging in hairless mice. Eur. J. Pharmacol., 602;148–56.
Fisher GJ, Talwar HS, Lin J, 1999. Molecular mechanisms of photo aging in human skin in vivo and their prevention by all-trans retinoic acid. Photochem. Photobiol., 69;154–7.
Angel P, Karin M, 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta., 1072;129–57.
Rittie L, Fisher GJ, 2002. UV-light-induced signal cascades and skin aging. Ageing Res. Rev., 1;705–20.
Whitmarsh AJ, Davis RJ, 1996. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med., 74;589–607.
Cesare DD, Jacquot S, Hanauer A, 1998. Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc. Natl. Acad. Sci. USA, 95;12202–7.
Derijard B, Hibi M, Wu IH, 1994. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell, 76;1025–37.
Bode AM, Dong Z, 2007. The functional contrariety of JNK. Mol. Carcinog., 46;591–8.
Gupta S, Barrett T, Whitmarsh AJ, 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J., 15;2760–70.
Sabapathy K, Wagner EF, 2004. JNK2: a negative regulator of cellular proliferation. Cell Cycle, 3;1520–3.
Jaeschke A, Karasarides M, Ventura JJ, 2006. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell, 23;899–911.
Horvathova K, Chalupa I, Sebova L, Tothova D, Vachalkova A, 2005. Protective effect of quercetin and luteolin in human melanomaHMB-2 cells. Mutat. Res., 565;105-112.
Huang SS, Liu SM, Lin SM, Liao PH, Lin RH, Chen YC, 2005. Antiarrhythmic effect of caffeic acid phenethyl ester (CAPE) on myocardial ischemia/reperfusion injury in rats. Clin. Biochem., 38;943 947.
Tsutsui H, Kinugawa S, Matsushima S, 2008. Oxidative stress and mitochondrial DNA damage in heart failure. Circ. J., 72;A31-A37.
Liao PH, Hung LM, Chen YH, Kuan YH, Zhang FB, Lin RH, 2011. Cardioprotective effects of luteolin during ischemiareperfusion injury in rats. Circ. J., 75;443-450.
Miura T, Miki T, 2009. GSK-3β, a therapeutic target for cardiomyocyte protection. Circ. J., 73;1184-1192.
Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM, 2005. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol., 288;H971-H976.
Published
Issue
Section
License
Copyright (c) 2017 Muhammad Faisal Manzoor, Nazir Ahmad, Ayesha, K
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journals offer different licence options, please see the Instructions to Authors page of the relevant journal for more information.
Books and book chapters
When publishing a book, or a chapter in a book, the terms of licensing and copyright will typically be included in a contract which you would have to agree with a publisher and which will specify the usage rights, the format(s) and length of time applied to the work.
Book contracts vary from publisher to publisher, and can in some cases be complicated. If you are required to sign a contract with a publisher in order to publish your work you need to ensure that the contract covers your rights and that it takes into account the obligation you have to your employer and/or the funder of your research.
If you want to publish a thesis or dissertation it is recommended that you contact your institution or department to make sure that you follow their policy for such publications.
Kindly Check the concern book title for How To Cite. Plese ignore if any citation format provided in Book Section
